Media.Player

Use Of Lipocalin-2 As A Diagnostic Marker And Therapeutic Target

Summary

Methods And Compositions For Identifying And Treating Obesity And Obesity-Induced Metabolic Disorders Are Provided. One Aspect Provides A Method For The Evaluation Of Risk And Progression Of Glucose Tolerance, Insulin Resistance And Type 2 Diabetes In Mammalian Subjects. The Method Includes Measuring The Concentration Of Circulating Lipocalin-2 In A Subject And Comparing The Measured Level To Lipocalin-2 To A Reference Level. Another Aspect Provides Methods Of Treating Insulin Resistance, Type 2 Diabetes And Other Related Complications By Administering To A Patient A Composition That Can Reduce The Circulating Levels Of Lipocalin-2, For Example A Lipocalin-2 Antagonist.

Supplementary Information

Patent Number: US7645616B2
Application Number: US2007875271A
Inventor: Xu, Aimin | Wang, Yu | Lam, Karen Siu Ling
Priority Date: 20 Oct 2006
Priority Number: US7645616B2
Application Date: 19 Oct 2007
Publication Date: 12 Jan 2010
IPC Current: G01N003353
US Class: 4350071 | 436811 | 43500792 | 436501
Assignee Applicant: The University of Hong Kong
Title: Use of lipocalin-2 as a diagnostic marker and therapeutic target
Usefulness: Use of lipocalin-2 as a diagnostic marker and therapeutic target
Summary: The methods are useful for diagnosing or assisting in diagnosing obesity or an obesity-induced metabolic disorder in a subject; screening substances useful for treating one or more symptoms of obesity or obesity-induced metabolic disorders; and treating or preventing one or more symptoms of obesity or an obesity-induced metabolic disorder. The composition can be used for the treatment of obesity or an obesity-induced metabolic disorder, and for the manufacture of a medicament for the treatment of obesity or an obesity-induced related disorder. The obesity-induced metabolic disorder is selected from elevated serum triglyceride, decreased high density lipoprotein (HDL)-cholesterol, hyperinsulinemia, atherosclerosis, insulin resistance, fasting glucose levels, Type 2 diabetes, or obesity-related inflammatory conditions (all claimed).
Novelty: Use of lipocalin-2 for diagnosing, treating, or preventing symptoms of obesity or an obesity-induced metabolic disorder, e.g. elevated serum triglyceride, decreased high density lipoprotein-cholesterol, or hyperinsulinemia

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

Application No.

US2007875271A

Country/Region

Hong Kong